Fatal candidemia caused by azole-resistant Candida tropicalis in patients with hematological malignancies

Journal of Infection and Chemotherapy

Volumn 18, Issue 5, 2012, Pages 741-746

  Chong, Yong ^a   Shimoda, Shinji ^b   Yakushiji, Hiroko ^a   Ito, Yoshikiyo ^a   Miyamoto, Toshihiro ^b   Shimono, Nobuyuki ^c   Kamimura, Tomohiko ^a   Akashi, Koichi ^b  

^a HARASANSHIN HOSPITAL   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY HOSPITAL   (Japan)

Author keywords

Azole; Candida tropicalis; Candidemia; Resistance

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; FLUCONAZOLE; FOSFLUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; VORICONAZOLE;

ACUTE LEUKEMIA; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CANDIDEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FATALITY; FEMALE; FUNGUS CULTURE; FUNGUS IDENTIFICATION; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION PREVENTION; LYMPHOMA; MALE; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; TREATMENT DURATION;

EID: 84871373379     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-012-0412-9     Document Type: Article

References (32)

1. Perea S, Patterson TF. Antifungal resistance in pathogenic fungi. Clin Infect Dis. 2002;35:1073-80.
2. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Meis JF, Gould IM, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol. 2007;45:1735-45.
3. Messer SA, Moet GJ, Kirby JT, Jones RN. Activity of contemporary antifungal agents, including the novel echinocandin anidulafungin, tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2006 to 2007). J Clin Microbiol. 2009;47:1942-6.
4. Takakura S, Fujihara N, Saito T, Kudo T, Iinuma Y, Ichiyama S. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J Antimicrob Chemother. 2004;53:283-9.
5. Takakura S, Fujihara N, Saito T, Kudo T, Iinuma Y, Ichiyama S. Clinical factors associated with fluconazole resistance and shortterm survival in patients with Candida bloodstream infection. Eur J Clin Microbiol Infect Dis. 2004;23:380-8.
6. Garnacho-Montero J, Diaz-Martin A, Garcia-Cabrera E, Ruiz Perez de Pipaon M, Hernandez-Caballero C, Aznar-Martin J, et al. Risk factors for fluconazole-resistant candidemia. Antimicrob Agents Chemother. 2010;54:3149-54.
7. Morace G, Sanguinetti M, Posteraro B, Pagano L. In vitro susceptibility of Candida species isolated from patients with haematological malignancies. Mycoses. 1995;38:59-67.
8. Nawrot U, Nowicka J, Juszczak K, Gusin B. Susceptibility to antifungal agents of Candida species isolated from paediatric and adult patients with haematological diseases. Mycoses. 2005;48:385-90.
9. Nawrot U, Nowicka J, Wlodarczyk K. Susceptibility to voriconazole, fluconazole, and ketoconazole of yeast isolated from patients with hematological malignancies. J Chemother. 2008;20:758-60.
10. Slavin MA, Sorrell TC, Marriott D, Thursky KA, Nguyen Q, Ellis DH, et al. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. J Antimicrob Chemother. 2010;65:1042-51.
11. Kontoyiannis DP, Vaziri I, Hanna HA, Boktour M, Thornby J, Hachem R, et al. Risk factors for Candida tropicalis fungemia in patients with cancer. Clin Infect Dis. 2001;33:1676-81.
12. Vigouroux S, Morin O, Moreau P, Harousseau JL, Milpied N. Candidemia in patients with hematologic malignancies: analysis of 7 years' experience in a single center. Haematologica. 2006;91:717-8.
13. Sipsas NV, Lewis RE, Tarrand J, Hachem R, Rolston KV, Raad II, et al. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer. 2009;115:4745-52.
14. Nucci M, Colombo AL. Candidemia due to Candida tropicalis: clinical, epidemiologic, and microbiologic characteristics of 188 episodes occurring in tertiary care hospitals. Diagn Microbiol Infect Dis. 2007;58:77-82.
15. Munoz P, Giannella M, Fanciulli C, Guinea J, Valerio M, Rojas L, et al. Candida tropicalis fungaemia: incidence, risk factors and mortality in a general hospital. Clin Microbiol Infect. 2011;17:1538-45.
16. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard-third edition (M27-A3). Wayne: CLSI; 2008.
17. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; third informational supplement (M27-S3). Wayne: CLSI; 2008.
18. Barnes AJ, Wardley AM, Oppenheim BA, Morgenstern GR, Scarffe JH, Warnock DW, et al. Fatal Candida tropicalis fungaemia in a leukaemic patient receiving fluconazole prophylaxis. J Infect. 1996;33:43-5.
19. Myoken Y, Kyo T, Fujihara M, Sugata T, Mikami Y. Clinical significance of breakthrough fungemia caused by azole-resistant Candida tropicalis in patients with hematologic malignancies. Haematologica. 2004;89:378-80.
20. Troughton JA, Browne G, McAuley DF, Walker MJ, Patterson CC, McMullan R. Prior colonisation with Candida species fails to guide empirical therapy for candidaemia in critically ill adults. J Infect. 2010;61:403-9.
21. Jang SJ, Han HL, Lee SH, Ryu SY, Chaulagain BP, Moon YL, et al. PFGE-based epidemiological study of an outbreak of Candida tropicalis candiduria: the importance of medical waste as a reservoir of nosocomial infection. Jpn J Infect Dis. 2005;58:263-7.
22. Donskey CJ. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin Infect Dis. 2004;39:219-26.
23. Wingard Jr. Fungal infections after bone marrow transplant. Biol Blood Marrow Transplant. 1999;5:55-68.
24. Vazquez JA, Dembry LM, Sanchez V, Vazquez MA, Sobel JD, Dmuchowski C, et al. Nosocomial Candida glabrata colonization: an epidemiologic study. J Clin Microbiol. 1998;36:421-6.
25. Myoken Y, Kyo T, Kohara T, Fujihara M, Sugata T, Mikami Y. Breakthrough fungemia caused by azole-resistant Candida albicans in neutropenic patients with acute leukemia. Clin Infect Dis. 2003;36:1496-7.
26. Myoken Y, Kyo T, Sugata T, Murayama SY, Mikami Y. Breakthrough fungemia caused by fluconazole-resistant Candida albicans with decreased susceptibility to voriconazole in patients with hematologic malignancies. Haematologica. 2006;91:287-8.
27. Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, et al. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by Clinical and Laboratory Standards Institute-recommended broth microdilution methods. J Clin Microbiol. 2007;45:70-5.
28. Magill SS, Shields C, Sears CL, Choti M, Merz WG. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol. 2006;44:529-35.
29. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSIrecommended methods. J Clin Microbiol. 2006;44:3533-8.
30. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr., Calandra TF, Edwards JE Jr., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503-35.
31. Pasquale T, Tomada JR, Ghannoun M, Dipersio J, Bonilla H. Emergence of Candida tropicalis resistant to caspofungin. J Antimicrob Chemother. 2008;61:219.
32. Garcia-Effron G, Kontoyiannis DP, Lewis RE, Perlin DS. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob Agents Chemother. 2008;52:4181-3.